Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Garmezy on Factors Influencing Treatment Selection in Variant RCC

April 9th 2024

Benjamin Garmezy, MD, discusses key factors influencing treatment selection for patients with variant renal cell carcinoma.

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC

April 9th 2024

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

April 8th 2024

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Dr Xu on Ongoing Biomarker Research in Metastatic RCC

April 5th 2024

Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.

Overview of Non–Clear Cell RCC

April 5th 2024

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Clinical Insights on Belzutifan in Advanced RCC

April 5th 2024

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Dr Grivas on Future Directions for Adjuvant Therapy Research in RCC

April 4th 2024

Petros Grivas, MD, PhD, discusses potential future directions for adjuvant therapies in patients with resected renal cell carcinoma.

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024

Stereotactic ablative body radiotherapy elicited high local control rates in patients with renal cell carcinoma who did not undergo surgical resection.

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

April 1st 2024

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC

April 1st 2024

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Key Takeaways on Updates in Bladder Cancer

April 1st 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Dr Bilusic on the Non-ccRCC Treatment Armamentarium

March 29th 2024

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

March 29th 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

March 29th 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Dr Merchán on the Role of Immunotherapy and TKI Combinations in RCC

March 28th 2024

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Dr Xu on Ongoing Research Initiatives in ccRCC

March 27th 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.